Paper Details

Paper Title

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.

Paper Journal Title

Invest New Drugs

Paper Citation Count

111

Paper Publication Year

2013

Bio Mention

(18)FDG, ADI, ADI-, ADI-PEG 20 antibody, ASS, Arginine, Arginine deiminase, Melanoma, Melanoma cells, PEG, Patients, SD, advanced melanoma, amino acid, arginine, arginine deiminase, argininosuccinate, argininosuccinate synthetase, argininosuccinatesynthetase, fatigue, melanoma, normal and neoplastic cells, patients, rash, tumor, uveal melanoma

Mesh Descriptor

Paper Details

Column Actions

Datasets